FACTORS INFLUENCING CONFORMITY INDEX IN RADIOTHERAPY FOR NON SMALL CELL LUNG CANCER

被引:10
|
作者
Brennan, Sinead M. [1 ]
Thirion, Pierre
Buckney, Steve
Shea, Carmel O.
Armstrong, John
机构
[1] St Lukes Hosp, Dept Radiat Oncol, Clin Trials Unit, Dublin 6, Ireland
关键词
Lung cancer; Radiotherapy; Conformity index; THERAPY ONCOLOGY GROUP; RADIATION-THERAPY; QUALITY-ASSURANCE; RADIOSURGERY; VOLUME;
D O I
10.1016/j.meddos.2009.01.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The radiotherapy conformity index (CI) is a useful tool to quantitatively assess the quality of radiotherapy treatment plans, and represents the relationship between isodose distributions and target volume. A conformity index of unity implies high planning target volume (PTV) coverage and minimal unnecessary irradiation of surrounding tissues. We performed this analysis to describe the CI for lung cancer 3-dimensional conformal radiotherapy (3DCRT) and to identify clinical and technical determinants of CI, as it is not known which factors are associated with good quality 3D conformal radiotherapy treatment planning. Radiotherapy treatment plans from a database of 52 patients with inoperable Stage 1 to 3b lung cancer, on a hypofractionated 3DCRT trial were evaluated. A CI was calculated for all plans using the definition of the ICRU 62:CI = (TV/PTV), which is the quotient of the treated volume (TV) and the PTV. Data on patient, tumor, and planning variables, which could influence CI, were recorded and analyzed. Mean CI was 2.01 (range = 1.06-3.8). On univariate analysis, PTV (p = 0.023), number of beams (p = 0.036), medial vs. lateral tumor location (p = 0.016), and increasing tumor stage (p = 0.041) were associated with improved conformity. On multiple regression analysis, factors found to be associated with CI included central vs. peripheral tumor location (p = 0.041) and PTV size (p = 0.058). The term 3DCRT is used routinely in the literature, without any indication of the degree of conformality. We recommend routine reporting of conformity indices. Conformity indices may be affected by both planning variables and tumor factors. (C) 2010 American Association of Medical Dosimetrists.
引用
收藏
页码:38 / 42
页数:5
相关论文
共 50 条
  • [1] Radiotherapy for inoperable non-small cell lung cancer using helical tomotherapy
    Monaco, Alessia
    Caruso, Cristina
    Giammarino, Daniela
    Cianciulli, Michele
    Pressello, Maria Cristina
    Donato, Vittorio
    TUMORI, 2012, 98 (01) : 86 - 89
  • [2] Predictive factors in radiotherapy for non-small cell lung cancer: present status
    Choi, N
    Baumann, M
    Flentjie, M
    Kellokumpu-Lehtinen, P
    Senan, S
    Zamboglou, N
    Kosmidis, P
    LUNG CANCER, 2001, 31 (01) : 43 - 56
  • [3] PROGNOSTIC FACTORS IN STEREOTACTIC BODY RADIOTHERAPY FOR NON-SMALL-CELL LUNG CANCER
    Matsuo, Yukinori
    Shibuya, Keiko
    Nagata, Yasushi
    Takayama, Kenji
    Norihisa, Yoshiki
    Mizowaki, Takashi
    Narabayashi, Masaru
    Sakanaka, Katsuyuki
    Hiraoka, Masahiro
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 79 (04): : 1104 - 1111
  • [4] Current landscape of palliative radiotherapy for non-small-cell lung cancer
    Jumeau, Raphael
    Vilotte, Florent
    Durham, Andre-Dante
    Ozsahin, Esat-Mahmut
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S192 - S201
  • [5] Innovations in the radiotherapy of non-small cell lung cancer
    Schild, Steven E.
    Bogart, Jeffery A.
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (01) : 85 - 92
  • [6] Non-small cell lung cancer.: Survival after radiotherapy and prognostic factors
    Olasolo, JJ
    Redondo, EA
    Jiménez, AL
    Ramos, AR
    ARCHIVOS DE BRONCONEUMOLOGIA, 2003, 39 (02): : 81 - 86
  • [7] Tumor Regression and Positional Changes in Non-small Cell Lung Cancer During Radical Radiotherapy
    Lim, Gerald
    Bezjak, Andrea
    Higgins, Jane
    Moseley, Doug
    Hope, Andrew J.
    Sun, Alex
    Cho, John B. C.
    Brade, Anthony M.
    Ma, Clement
    Bissonnette, Jean-Pierre
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (03) : 531 - 536
  • [8] Survival and prognostic factors after moderately hypofractionated palliative thoracic radiotherapy for non-small cell lung cancer
    van Oorschot, B.
    Assenbrunner, B.
    Schuler, M.
    Beckmann, G.
    Flentje, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2014, 190 (03) : 270 - 275
  • [9] New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer
    Luna, Javier
    Zafra, Juan
    Areses Manrique, Ma Carmen
    Rodriguez, Aurora
    Sotoca, Amalia
    Firvida, Jose Luis
    Chicas-Sett, Rodolfo
    Mielgo, Xabier
    Reyes, Juan Carlos Trujillo
    Counago, Felipe
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2021, 12 (11): : 983 - 999
  • [10] Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer
    Wujanto, Caryn
    Vellayappan, Balamurugan
    Siva, Shankar
    Louie, Alexander V.
    Guckenberger, Matthias
    Slotman, Ben J.
    Onishi, Hiroshi
    Nagata, Yasushi
    Liu, Mitchell
    Lo, Simon S.
    FRONTIERS IN ONCOLOGY, 2019, 9